The Repurposing

Researchers at Tohoku University found that lubiprostone, a generic constipation drug, unexpectedly slows the decline of chronic kidney disease. The study revealed the drug preserves kidney function by reshaping the gut microbiome, rather than by clearing uremic toxins as initially hypothesized.